Effectiveness of antidementia drugs in delaying Alzheimer's disease progression

[1]  L. Schneider,et al.  Lack of evidence for the efficacy of memantine in mild Alzheimer disease. , 2011, Archives of neurology.

[2]  A. Nobili,et al.  Cholinesterase inhibitor use in Alzheimer's disease: the EPIFARM‐Elderly Project , 2011, Pharmacoepidemiology and drug safety.

[3]  Philip S. Insel,et al.  Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative. , 2011, Archives of neurology.

[4]  C. Wattmo,et al.  Long-term Outcome and Prediction Models of Activities of Daily Living in Alzheimer Disease With Cholinesterase Inhibitor Treatment , 2011, Alzheimer disease and associated disorders.

[5]  P. Tariot,et al.  Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study. , 2010, Clinical therapeutics.

[6]  Richard Mayeux,et al.  Clinical practice. Early Alzheimer's disease. , 2010, The New England journal of medicine.

[7]  W. Chan,et al.  Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease , 2009, Alzheimers Res Ther.

[8]  J. Becker,et al.  Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease , 2009, Journal of Neurology, Neurosurgery, and Psychiatry.

[9]  D. Wilkins.  IS IT TIME TO USE OBSERVATIONAL DATA TO ESTIMATE TREATMENT EFFECTIVENESS IN MULTIPLE SCLEROSIS? , 2008, Neurology.

[10]  A. Atri,et al.  Long-term Course and Effectiveness of Combination Therapy in Alzheimer Disease , 2008, Alzheimer disease and associated disorders.

[11]  J. Cummings,et al.  A Modern Hypothesis: The Distinct Pathologies of Dementia Associated with Parkinson’s Disease versus Alzheimer’s Disease , 2008, Dementia and Geriatric Cognitive Disorders.

[12]  J. Olin,et al.  Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. , 2008, Current Alzheimer research.

[13]  S. E. Black,et al.  Donepezil preserves cognition and global function in patients with severe Alzheimer disease , 2007, Neurology.

[14]  D. Wilkinson,et al.  Analysis of the Effect of Memantine in Reducing the Worsening of Clinical Symptoms in Patients with Moderate to Severe Alzheimer’s Disease , 2007, Dementia and Geriatric Cognitive Disorders.

[15]  Roy W Jones,et al.  Memantine in Moderate to Severe Alzheimer’s Disease: a Meta-Analysis of Randomised Clinical Trials , 2007, Dementia and Geriatric Cognitive Disorders.

[16]  P. Tariot,et al.  A 24-week Randomized, Controlled Trial of Memantine in Patients With Moderate-to-severe Alzheimer Disease , 2007, Alzheimer disease and associated disorders.

[17]  P. Tariot,et al.  Meta-analysis of six-month memantine trials in Alzheimer’s disease , 2007, Alzheimer's & Dementia.

[18]  R. Doody,et al.  Influence of Premorbid IQ and Education on Progression of Alzheimer’s Disease , 2006, Dementia and Geriatric Cognitive Disorders.

[19]  M. Sano,et al.  Realistic expectations for treatment success in Alzheimer's disease. , 2006, The journal of nutrition, health & aging.

[20]  Steven G Potkin,et al.  Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. , 2006, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[21]  Sture Eriksson,et al.  Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study , 2006, The Lancet.

[22]  J. Birks,et al.  Cholinesterase inhibitors for Alzheimer's disease. , 2006 .

[23]  M. Farlow,et al.  Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years , 2005, BMC geriatrics.

[24]  P. Rothwell,et al.  External validity of randomised controlled trials: “To whom do the results of this trial apply?” , 2005, The Lancet.

[25]  B. Seltzer,et al.  Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial. , 2004, Archives of neurology.

[26]  C. Holmes,et al.  The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease , 2004, Neurology.

[27]  J. Raftery,et al.  Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial , 2004, The Lancet.

[28]  K. Rockwood,et al.  Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer’s disease , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[29]  E. Peskind,et al.  The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial. , 2004, Archives of neurology.

[30]  Pierre N Tariot,et al.  Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. , 2004, JAMA.

[31]  Richard Birtwhistle,et al.  Pragmatic controlled clinical trials in primary care: the struggle between external and internal validity. , 2003, BMC medical research methodology.

[32]  M. Kataki,et al.  A Method for Estimating Duration of Illness in Alzheimer’s Disease , 2003, Dementia and Geriatric Cognitive Disorders.

[33]  J. Kornhuber,et al.  Memantine in moderate-to-severe Alzheimer's disease. , 2003, The New England journal of medicine.

[34]  M. Kane.  Awareness of ageism, motivation, and countertransference in the care of elders with Alzheimer's disease , 2002, American journal of Alzheimer's disease and other dementias.

[35]  H. Feldman,et al.  A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease , 2001, Neurology.

[36]  Dirk Deleu,et al.  A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. , 2001, Neurology.

[37]  B. Winblad,et al.  A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD , 2001, Neurology.

[38]  R. Mohs,et al.  A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients , 2001, Neurology.

[39]  B. Gordon,et al.  Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. , 2001, Archives of neurology.

[40]  G. Wilcock,et al.  Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial , 2000, BMJ : British Medical Journal.

[41]  M. Farlow,et al.  A 52-Week Study of the Efficacy of Rivastigmine in Patients with Mild to Moderately Severe Alzheimer’s Disease , 2000, European Neurology.

[42]  E. Peskind,et al.  Galantamine in AD , 2000, Neurology.

[43]  R. Doody,et al.  Long-term efficacy and safety of donepezil in the treatment of Alzheimer’s disease: final analysis of a US multicentre open-label study , 2000, European Neuropsychopharmacology.

[44]  D. Jolley,et al.  VI. STIGMA AND ALZHEIMER'S DISEASE: CAUSES, CONSEQUENCES AND A CONSTRUCTIVE APPROACH , 2000, International journal of clinical practice.

[45]  B. Winblad.  Harmonisation of availability of drugs for Alzheimer's disease , 1999, The Lancet.

[46]  P Dal-Bianco,et al.  Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. , 1999, BMJ.

[47]  Y. Agid,et al.  Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trialCommentary: Another piece of the Alzheimer's jigsaw , 1999 .

[48]  R. Mohs,et al.  Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. , 1998, Archives of internal medicine.

[49]  R. Mohs,et al.  A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease , 1998, Neurology.

[50]  K. Davis.  Cholinesterase Inhibitors in Alzheimer's Disease , 1994, Neuropsychopharmacology.

[51]  S. Bakchine,et al.  Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study. , 2008, Journal of Alzheimer's disease : JAD.

[52]  P. Mecocci,et al.  Pooled analyses on cognitive effects of memantine in patients with moderate to severe Alzheimer's disease. , 2008, Journal of Alzheimer's disease : JAD.

[53]  K. Lohr,et al.  Functional Outcomes of Drug Treatment in Alzheimer’s Disease , 2007, Drugs & aging.

[54]  B. Reisberg,et al.  A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. , 2006, Archives of neurology.

[55]  F. Sherriff,et al.  Memantine for dementia. , 2005, The Cochrane database of systematic reviews.

[56]  G. Wilcock,et al.  Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. , 2000, BMJ.

[57]  Vijaya L. Melnick,et al.  Alzheimer’s Dementia , 1985, Contemporary Issues in Biomedicine, Ethics, and Society.